BC
NTLA icon

Bayforest Capital’s Intellia Therapeutics NTLA Stock Holding History

Bayforest Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.7K Buy
+6,370
New +$81.1K 0.09% 423
2025
Q4 		– Sell
-262
Closed -$4.53K – 903
2025
Q3 		$4.53K Buy
+262
New +$3.23K ﹤0.01% 698
2025
Q1 		– Sell
-2,496
Closed -$29.1K – 846
2024
Q4 		$29.1K Buy
+2,496
New +$39K 0.04% 540

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bayforest Capital's NTLA Position: Q1 2026 in Review

Bayforest Capital opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 6,370 shares worth $81.7K. The stake represents 0.09% of the portfolio and ranks #423 among its holdings. This is a return to the name: Bayforest Capital previously reported a position in NTLA as recently as Q3 2025.

Bayforest Capital first reported a position in NTLA in Q4 2024 and has held it in 3 quarters since. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Bayforest Capital held 6,370 shares of Intellia Therapeutics worth $81.7K as of Q1 2026.
  • Intellia Therapeutics was a new Bayforest Capital position in Q1 2026.
  • Intellia Therapeutics made up 0.09% of Bayforest Capital's portfolio in Q1 2026, its #423 holding.
  • Bayforest Capital first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.